Douglas Munsey

Current Fund Investments Include: - CellFE Biotech (www.cellfebiotech.com) - DesiCorp (https://www.desicorpinc.com) - Coformer.ai (https://www.coformer.ai/) - Izote Biosciences (https://izote.bio) - SoFab Inks (https://sofabinks.com) - MiLaboratories (https://milaboratories.com) - Circe (https://www.circebioscience.com) - Syntax Bio (www.syntax-bio.com) - Sironix Renewables (sironixrenewables.com) - Fork & Good (forkandgood.com) - DINYA DNA (www.dinyadna.com) - SWAN Genomics - RiboForge (www.riboforge.com) - Extellis (www.extellis.com) - Heritable Agriculture (https://heritable.ag) - Biotia (https://www.biotia.io) - Sift Bio (https://siftbio.com) - Novel Bio (www.novel-bio.com) Additional Family Office Investments: - Converse Health (https://www.converse.health) - C. Light Technologies (https://www.clighttechnologies.com) - Coherence.ai (coherenceai.com) - Horizon Blockchain (horizon.io) - Exokeryx (exokeryx.com) - Petal Surgical (https://www.petalsurgical.com) LP Commitments: - Studio VC - Kayne Anderson - SBVP - Generous Ventures - Morgan Stanley Expansion Capital

Touchdown Ventures is a venture capital firm that partners with leading corporations to launch and manage their corporate venture capital investment programs. Our partners are typically leaders in their industries, including CPG, telecommunications, industrial, professional services and media & entertainment, among others. Our capabilities include managing the complete lifecycle of venture capital from entity formation to investment management (strategy, sourcing, deal flow, diligence, investment approvals, transacting, portfolio management, liquidity, internal communications, and reporting, etc.). Learn more on our website: www.touchdownvc.com

Passed the majority of day to day decision making on to COO. I assist with overall direction and strategy.

Changing the prescription paradigm in complex rehabilitation using cutting edge computer vision and 3d reconstruction technology • Led team through the product development cycle - assessed customer needs, defined the value proposition, oversaw development, and conducted beta testing to create a unique product capable of improving healthcare professional’s accuracy in prescribing rehabilitation devices and significantly improving patient outcomes • Analyzed industry dynamics, built financial models and a viable business plan, pitched the company to potential investors, negotiated term sheets, and ultimately raised $550K in funding which allowed us to begin operations • Established the structure of the business which is subject to complicated legal and regulatory requirements, including End-User Licenses, Terms of Service, BAA’s, and other HIPAA compliance provisions • Negotiated and executed agreement to exclusively supply the largest national complex rehabilitation distributor in North America for one year in exchange for a 90% adoption rate among its over 400 technical practitioners

Syntax Bio is developing a proprietary genetic programming platform technology that converts cells into biological computers using DNA based instructions that read like lines of code

CellFE has developed a scalable, high throughput microfluidic device for the efficient delivery of gene-editing molecules into cells. Guided CellFE from ideation and customer discovery to a $4.8M seed round by led by Dynamk Capital and Cota Capital, with participation from Elm Street Ventures, and Embark Ventures.

As one of the first employees helping grow Ki from a small startup to a company with hundreds of employees I served as in-house strategic consultant, improving underperforming departments and performing analysis on topics including real estate transactions, acquisitions, loan structures, foreign investments, and distribution agreements.

Working to commercialize exciting technologies in wound care Offer guidance and analysis on financial modeling, deal structuring & due diligence, corporate strategy, and capital raises

The materials revolution comes to surfing, and it's about time Created company model to determine operating forecasts, peak cash requirements, budget restraints, optimal timing of expenditures and capital raises, and key financial milestones Analyzed industry dynamics, developed budgeting scenarios, created funding strategies and potential milestones, and identified customer access routes to develop an operating strategy

• Assumed the primary associate role on coverage of the Hospital Supply/Orthopedic coverage universe; JNJ, COV, HSP, BDX, IART, SYK, ZMH, NUVA, MAKO, ETRM • Created comprehensive and dynamic financial models for five medical technology companies (JNJ, IART, BDX, COV, HSP) to allow for evaluation of financial health, and to assign probability weighted values to common equity (Published September 2008) • Performed an in-depth pre-initiation overview of the business model, management competence and incentives, ongoing and upcoming clinical trials, current product lines, and financial integrity of Integra LifeScienes (Published September 2008) • Modeled pro forma accretion/dilution impact of acquisitions, capital infusions, and other corporate transactions for different cash/stock mixes and execution scenarios • Evaluated distribution agreement between JNJ/SGP to determine effects of proposed SGP/MRK merger (Published March 2009) • Conducted extensive analysis of the earnings potential of Covidien (Published February 2009)